

Assessment oxidative stress and some antioxidants in hypothyroidism women before and after treatment with Levothyroxine

Almoanna Ahmed Hammod¹, Nuha Ali Hadi Al_Samarrai¹

1- Department of Chemistry, College of Education, University of Samarra, Samarra - Salah Eldin, Iraq.



This work is licensed under a [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/)

<https://doi.org/10.54153/sjpas.2026.v8i1.1216>

Article Information

Received: 19/04/2025

Revised: 20/05/2025

Accepted: 21/06/2025

Published: 10/04/2026

Keywords:

Hypothyroidism women, levothyroxine, oxidative stress, antioxidants, thyroid stimulating hormone, Thyroxine (T4) and triiodothyronine (T3)

Corresponding Author

E-mail:

eduhm230031@uosamarra.edu.iq

Mobile:

Abstract

Background: Thyroid hormones influence the majority of bodily functions by directly impacting various physiological processes and the operation of numerous tissues. They are essential for the operation of other hormones. Aim of the study : Assessment level of glutathione (GSH), glutathione peroxidase (GSH-PX), and malondialdehyde (MDA), Thyroxine (T4) and triiodothyronine (T3), and lipid profile in hypothyroidism women before and after treatment with levothyroxine. Materials and methods: 60 women (before and after taking Levothyroxine treatment) and 30 control group were selected for the study. The study sample was selected from (15-54) years for the period from the end of September 2024 to the beginning of March 2025. Samples were taken from people who visit specialists in outpatient clinics and health centers in Samarra city. Result: The serum levels of GSH, GSH-PX, and MDA in hypothyroid women before and after treatment were significantly distinct from those in the control group ($p < 0.001$). The lipid profiles, including total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol, in the serum of hypothyroid women exhibited significant differences from those of the control group before and after treatment ($p = 0.01$). Thyroid hormone levels (TSH, T3, and T4) exhibited a substantial rise ($p < 0.01$) in the serum of hypothyroid women pre- and post-treatment in comparison to the control group. Conclusion: The current study concluded increase MDA in patient with hypothyroidism before treatment, while decrease after treatment. In contrast decrease both GSH, GSH-PX, and HDL in in women with hypothyroidism before treatment, while increase after treatment.

Introduction:

The thyroid gland is among the largest endocrine glands in the body, weighing roughly 15 to 20 grams in a typical adult(1). It secretes two principal hormones essential for the proper functioning of several physiological processes that influence nearly every organ system in the body(2). The secretion of thyroid hormones is regulated by the hypothalamic-pituitary-thyroid (HPT) axis(3).

Numerous biochemical events occur within our body to sustain homeostasis, facilitate growth, promote healing, and avert illnesses. These reactions produce deleterious chemicals and radicals, termed free radicals, which can modify nearby cellular structures, hence impacting cellular function. Consequently, the innate defense mechanism, comprising the antioxidant system, operates continuously against free radicals. The disruption of the equilibrium between free radical production and antioxidant activity leads to oxidative stress (OS) (4).

The existing data about oxidative stress and antioxidant capability in hypothyroidism are limited and contentious. Certain authors propose that tissues might be safeguarded from oxidative damage due to a hypometabolic condition in hypothyroidism (5), whereas other research indicate that oxidative stress is elevated in hypothyroidism (6). Moreover, the degradation of peroxidized lipids produces a diverse array of end-products, including MDA (7). Consequently, the measurement of MDA is extensively utilized as a marker of lipid peroxidation (8). Elevated concentrations of lipid peroxidation products have been linked to numerous illnesses in both humans and experimental systems (9).

Materials and Method

This study was conducted in Samarra city, where samples were randomly collected from females with hypothyroidism between late September 2024 and early March 2025. Samples were taken from individuals visiting specialists in outpatient clinics and health centers in Samarra city. A total of 90 samples were collected.

Group Patient

60 samples were collected from hypothyroid women aged (15-54) years. Blood samples were taken for two periods: when they were diagnosed with hypothyroidism by a specialist doctor and after 3 months of taking Levothyroxine treatment. A questionnaire was used to record personal information for each of them.

Control Group

30 samples were collected from women who were not suffering from hypothyroidism, their ages ranged between (15-54) years, and they were selected from the residents of Samarra city.

Collection of Blood samples

5 ml of blood was taken from diseased women and control group members. Blood was inserted in a sterile 10 ml gel tube without anticoagulant to separate serum. After 30 minutes at lab temperature, it was centrifuged at 2500 rpm for 10 minutes to extract serum, which was extracted with an automated pipette. The serum was placed in three Eppendorf tubes, firmly sealed, and stored at -20°C until use.

Assessment of biochemical variable

Both groups were tested for MDA, GSH and GSH-PX using BT (Bioassay Technology Laboratory) ELISA kits from China. Estimate the concentration of TSH, T3, and T4 hormone in the blood serum using a ready-made analysis kit provided by VEDA.LAB-France. The BIOLABO reagent kit was used to quantify serum TC, TG, HDL, and LDL in accordance with the method described by(10).

Statistical analysis

The data was statistically examined using SPSS software version 27 (SPSS, Inc.) and the Analysis of Variance (ANOVA) test. The goal was to find out how significant the differences were between the control group and the hypothyroidism women.

Results and Discussion

The total number of patients participating in the study was 60 patients with hypothyroidism and 30 healthy control subjects. This study showed that the peak age of patients with hypothyroidism was between 35-54 years, representing 50% of the total, while the lowest age group was between 25-34 years, representing 13%, according to Table (1).

Table (1): Relationship of hypothyroidism patients with age.

Age groups	No	%
15-24	8	13%
25-34	22	37%
35-54	30	50%
Total	60	100%
P-Value = 0.050		

Hypothyroidism women sera were compared to healthy people's for GSH, GSH-PX, and MDA levels before and after treatment with levothyroxine. Table (2) shows a 0.01 P-Value difference.

Table (2): Comparison of the levels of GSH, GSH-PX and MDA in the sera of women with hypothyroidism before and after treatment with levothyroxine and the control groups

Study groups	No	Mean \pm SD		
		GSH-PX	GSH	MDA
		U\g	nmol/ml	Nmol\g
Before treatment	60	0.64 \pm 0.11	28.81 \pm 5.31	5.46 \pm 0.60
After treatment	60	0.94 \pm 0.41	35.83 \pm 6.04	2.59 \pm 0.44
Control	30	0.85 \pm 0.32	48.82 \pm 12.02	1.83 \pm 0.76
P. value		0.01	0.01	0.01

Lipid profiles TC, TG, LDL , HDL were measured in the serum of hypothyroid women before and after treatment with levothyroxine and compared to healthy control. The results, as shown in Table (3), showed a significant difference (P-value = 0.01). However, no significant differences (P-value = 0.06) were recorded in the serum of VLDL women before and after treatment compared to the control groups.

Table (3): Comparison of the TC, TG, LDL , HDL, and VLDL in the sera of women with hypothyroidism before and after treatment with levothyroxine and the control groups.

Study groups	No	Mean \pm SD				
		Cholesterol mg/dl	TG mg/dl	LDL mg/dl	VLDL mg/dl	HDL mg/dl
Before treatment	60	223.10 \pm 11.72	132.03 \pm 36.58	152.87 \pm 13.79	26.40 \pm 7.31	35.51 \pm 1.90
After treatment	60	203.77 \pm 9.09	121.05 \pm 4.25	128.57 \pm 10.41	24.08 \pm 1.15	50.55 \pm 3.32
Control	30	175.53 \pm 9.44	106.40 \pm 8.93	106.84 \pm 10.46	21.28 \pm 1.78	47.93 \pm 2.80
P. value		0.01	0.01	0.01	0.06	0.01

Thyroid hormone levels (TSH, T4, and T3) were measured in the serum of hypothyroid women before and after treatment compared with the control groups. The results were shown in Table (4) with a significant difference (P-value = 0.01).

Table (4) Comparison of thyroid hormones (TSH, T4, and T3) in the serum of hypothyroid women before and after treatment with levothyroxine and compared with the control groups.

Study groups)	No	Mean \pm SD		
		TSH mU/L	T4 ng\dl	T3 ng\dl
Before treatment	60	15.66 \pm 3.66	7.18 \pm 3.59	1.46 \pm 0.42
After treatment	60	3.29 \pm 0.76	11.80 \pm 2.05	3.18 \pm 0.77
Control	30	2.91 \pm 0.48	13.14 \pm 1.14	3.30 \pm 0.37
P. value		0.01	0.01	0.01

This study reveals that the highest rate of hypothyroidism among women was in the 35-54 age group, and the lowest rate was in the 15-24 age group. This gender disparity, which is attributed to the higher prevalence in females, may be related to the hormones estrogen and progesterone. A study done by(11) that the highest prevalence of thyroid disease was found in middle-aged women in their forties. This data is consistent with ours, as more female patients were diagnosed with thyroid abnormalities. Oxidative stress is a condition characterized by an imbalance between oxidative and antioxidant levels. This phenomenon is prevalent in various illnesses, including pre-treatment thyroid dysfunction, and can result in increased quantities of reactive oxygen species, such as hydrogen peroxide, which induce protein degradation and contribute to disease. In individuals with hypothyroidism, the

likelihood of dyslipidemia, metabolic syndrome, and atherosclerosis is heightened due to elevated oxidative stress (12).

The present investigation revealed a favorable correlation between hypothyroidism and MDA levels prior to treatment. This conclusion aligns with research by (13) indicating that reactive oxygen species induce lipid peroxidation, resulting in MDA formation, which contributes to oxidative damage and oxidative stress in hypothyroid individuals. MDA can be utilized to detect oxidative stress linked to hypothyroidism and to monitor the condition post-treatment with L-thyroxine, as its levels diminish with therapy, as evidenced by multiple research.

The present investigation demonstrated that GSH levels in hypothyroid patients are markedly lower than in healthy controls, corroborating findings from (14). The significance of thyroid hormone in the production of antioxidant agents, such as GSH, indicates that diminished thyroid hormone levels result in a reduction of GSH biosynthesis. Additionally, diminished GSH levels may result from several reasons, including reduced superoxide dismutase levels, which contribute to superoxide buildup, superoxide oxidation, and GSH oxidation. A study conducted by (15) revealed that increasing oxidative stress correlates with a reduction in the antioxidant activity levels of superoxide dismutase and GSH-PX in patients with hypothyroidism.

Hypothyroidism plays a role in the development of metabolic syndrome. It is likely that thyroid hormones influence body fat percentage, causing elevated blood lipids, and that excess fat acts as a substrate for T3. As a result, T3 consumes oxygen at a faster rate, leading to increased production of reactive oxygen species (ROS), increased cellular antioxidant consumption, and inactivation of antioxidant enzymes(16). The metabolic depression caused by hypothyroidism reduces the production of reducing oxidants, thus protecting tissues from their resulting damage (17).

Estradiol plays a role in the pathophysiology of hypothyroidism and has an antagonistic effect on the activity of the antagonistic hormones T3 and T4 by competing with them for their binding receptors. Therefore, there may be a decrease in circulating T3 and T4 activity, which could lead to hypothyroidism. These findings are consistent with the previous study by (18). The current findings indicated a notable reduction in T3 and T4 thyroid hormone levels, alongside a considerable elevation in TSH levels in obese and overweight patients prior to treatment, in comparison to the healthy control group. This result aligns with the conclusions of (19).Marginally raised serum TSH levels correlated with a heightened prevalence of obesity. The thyroid gland exerts a significant biological influence on various bodily functions, including growth, reproduction, and metabolic regulation (20). Thyroxine-induced thermogenesis is ascribed to an elevated demand for ATP due to heightened cellular activity and diminished efficiency in ATP production. Consequently, hypothyroid patients have diminished and delayed metabolic activity, frequently resulting in an elevated body mass index (BMI). Prior studies have associated hypothyroidism with elevated oxidative stress; it was found that heightened oxidative stress may adversely impact the thyroid follicular cells responsible for secreting T3 and T4, resulting in decreased blood levels of these hormones and higher TSH levels (21). A study indicated that elevated blood TSH levels and higher T4 levels were correlated with hypothyroidism in relation to advancing age (22).

Conclusion

The current study concluded increase MDA in patient with hypothyroidism before treatment, while decrease after treatment. In contrast decrease both GSH, GSH-PX, and HDL in patient with hypothyroidism before treatment, while increase after treatment.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Salaam A, Danjem S, Salaam A, Angba H, Ibinaiye P. Determination of Normal Thyroid Gland Volume On Ultrasound In Normal Adults In Jos, North Central Nigeria. *International Journal of Scientific and Research Publications*. 2020;10(1):44-54.
2. Meah F, Lundholm M, Emanuele N, Amjed H, Poku C, Agrawal L, et al. The effects of cannabis and cannabinoids on the endocrine system. *Reviews in Endocrine and Metabolic Disorders*. 2022;23(3):401-20.
3. Bhanothu V, Fernandes S, Rao SC, Keshwani R, Shagun SW, Surve S, et al. Use of Allele-Specific-Amplification Refractory Mutation System–Polymerase Chain Reaction for the Detection of Thyroid-Stimulating Hormone Receptor Gene Mutation in an Indian Family with Thyroid Dysmorphogenesis. *Annals of Neonatology*. 2024;6(1):7-36.
4. Nanda N. Oxidative stress in hypothyroidism. *International Journal of Clinical and Experimental Physiology*. 2016;3(1):4-9.
5. Pereira B, Rosa LC, Safi D, Bechara EJH, Curi R. Control of superoxide dismutase, catalase and glutathione peroxidase activities in rat lymphoid organs by thyroid hormones. *Journal of Endocrinology*. 1994;140(1):73-7.
6. Sundaram V, Hanna AN, Koneru L, Newman H, Falko JM. Both hypothyroidism and hyperthyroidism enhance low density lipoprotein oxidation. *The Journal of Clinical Endocrinology & Metabolism*. 1997;82(10):3421-4.
7. Gambhir JK, Lali P, Jain AK. Correlation between blood antioxidant levels and lipid peroxidation in rheumatoid arthritis. *Clinical biochemistry*. 1997;30(4):351-5.
8. Draper H, Hadley M. A review of recent studies on the metabolism of exogenous and endogenous malondialdehyde. *Xenobiotica*. 1990;20(9):901-7.
9. Romero FJ, Bosch-Morell F, Romero MJ, Jareño EJ, Romero B, Marín N, et al. Lipid peroxidation products and antioxidants in human disease. *Environmental health perspectives*. 1998;106(suppl 5):1229-34.
10. Omari A. Relation between Serum Homocysteine Level and Lipid Profile in Patients with Dyslipidemia. *Education*. 2002;2004.
11. Hossen, Muhammad Shahadat, et al. "Thyroid Dysfunction Prevalence and Risk Factors in the Southeastern Part of Bangladesh: A Cross-Sectional Study." *Health Science Reports* 8.1 (2025): e70329.

12. Sankha S, Kumar YM, Madhuri AA, Kumar MT. Antioxidant status and oxidative stress in hypothyroidism. *Journal of Datta Meghe Institute of Medical Sciences University*. 2021;16(3):508-14.
13. Ruggeri RM, Giovinazzo S, Barbalace MC, Cristani M, Alibrandi A, Vicchio TM, et al. Influence of dietary habits on oxidative stress markers in Hashimoto's thyroiditis. *Thyroid*. 2021;31(1):96-105.
14. Prabhu KA, Rao YD, Sowndarya K, Nandini M. Assessment of Oxidative Stress Index in Sub-Clinical Hypothyroidism. *Biomedical and Pharmacology Journal*. 2021;14(2):739-49.
15. Rada F. Inference of oxidative stress in patients with hypothyroidism. *European Journal of Clinical and Experimental Medicine*. 2024;22(2):270-4.
16. Murgod R, Soans G. Changes in electrolyte and lipid profile in hypothyroidism. *Int J Life Sci Pharma Res*. 2012;2(3):185-94.
17. Kim B. Thyroid hormone as a determinant of energy expenditure and the basal metabolic rate. *Thyroid*. 2008;18(2):141-4.
18. Shantha GPS, Kumar AA, Jeyachandran V, Rajamanickam D, Rajkumar K, Salim S, et al. Association between primary hypothyroidism and metabolic syndrome and the role of C reactive protein: a cross-sectional study from South India. *Thyroid research*. 2009;2:1-7.
19. Stipanuk M. *Biochemical and Physiological Aspects of Human Nutrition*. Pennsylvania. Philadelphia: WB Saunders Company, USA; 2000.
20. Mansoor R, Rizvi S, Kausar W, Aslam F, Huda S. Comparison of TSH, T4 and T3 levels in primary hypothyroidism in relation to gender and age in a tertiary care hospital. *Ann Pak Inst Med Sci*. 2011;7(4):186-90.
21. Mahadik K, Choudhary P, Roy P. Study of thyroid function in pregnancy, its fetomaternal outcome; a prospective observational study. *BMC pregnancy and childbirth*. 2020;20:1-7.
22. Varner MW, Mele L, Casey BM, Peaceman AM, Reddy UM, Wapner RJ, et al. Progression of gestational subclinical hypothyroidism and hypothyroxinemia to overt hypothyroidism after pregnancy: pooled analysis of data from two randomized controlled trials. *Thyroid*. 2024;34(9):1171-6.

تقييم الإجهاد التأكسدي وبعض مضادات الأكسدة لدى النساء المصابات بقصور الغدة الدرقية قبل وبعد العلاج بالليفوثيروكسين

المعنى احمد حمود^{1*}، نهى علي هادي السامرائي¹

1- قسم الكيمياء، كلية التربية للعلوم الصرفة، جامعة سامراء، سامراء، العراق

الخلاصة:

تؤثر هرمونات الغدة الدرقية على معظم وظائف الجسم من خلال التأثير المباشر على العمليات الفسيولوجية المختلفة وعمل العديد من الأنسجة. وهي ضرورية لعمل الهرمونات الأخرى. تقييم مستوى الجلوتاثيون (GSH)، والجلوتاثيون بيروكسيداز (GSH-PX)، والمالونديالدهيد (MDA)، والثيروكسين (T4) وثلاثي يودوثيرونين (T3)، ومستوى الدهون في النساء المصابات بقصور الغدة الدرقية قبل وبعد العلاج بالليفوثيروكسين. تم اختيار 60 مريضة (قبل وبعد تناول علاج الليفوثيروكسين) و30 مجموعة ضابطة للدراسة. تم اختيار عينة الدراسة من (15-54) عامًا للفترة من نهاية سبتمبر 2024 إلى بداية مارس 2025. تم أخذ العينات من الأشخاص الذين يزورون المتخصصين في العيادات الخارجية والمراكز الصحية في مدينة سامراء. كانت مستويات مصل GSH و GSH-PX و MDA في مرضى قصور الغدة الدرقية قبل العلاج وبعده مختلفة بشكل كبير عن تلك الموجودة في المجموعة الضابطة ($p < 0.001$). أظهرت ملفات تعريف الدهون، بما في ذلك الكوليسترول الكلي والدهون الثلاثية وكوليسترول البروتين الدهني منخفض الكثافة (LDL) وكوليسترول البروتين الدهني عالي الكثافة (HDL)، في مصل مرضى قصور الغدة الدرقية اختلافات كبيرة عن تلك الموجودة في المجموعة الضابطة قبل العلاج وبعده ($p = 0.01$). أظهرت مستويات هرمون الغدة الدرقية (TSH و T3 و T4) ارتفاعًا كبيرًا ($p < 0.01$) في مصل مرضى قصور الغدة الدرقية قبل العلاج وبعده مقارنةً بالمجموعة الضابطة. وخلصت الدراسة الحالية إلى زيادة MDA في المرضى الذين يعانون من قصور الغدة الدرقية قبل العلاج، بينما انخفضت بعد العلاج. وعلى النقيض من ذلك، انخفض كل من GSH و GSH-PX و HDL في المرضى الذين يعانون من قصور الغدة الدرقية قبل العلاج، بينما زادت بعد العلاج.

معلومات البحث:

تاريخ الاستلام: 2025/04/19

تاريخ التعديل: 2025/05/20

تاريخ القبول: 2025/06/21

تاريخ النشر: 2026/04/10

الكلمات المفتاحية:

مرضى قصور الغدة الدرقية، ليفوثيروكسين، الإجهاد التأكسدي، مضادات الأكسدة، هرمون تحفيز الغدة الدرقية، الثيروكسين (T4) وثلاثي يودوثيرونين (T3)

معلومات المؤلف

الايمل:

eduhm230031@uosamarra.edu.iq

الموبايل: